Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 October 2022 | Story Samkelo Fetile | Photo Supplied
Dr Sevias Guvurio
Dr Sevias Guvuriro.

Dr Sevias Guvuriro from the Faculty of Economic and Management Sciences at the University of the Free State (UFS) is the first UFS candidate to participate in the University of Michigan African Presidential Scholarship (UMAPS) fellowship programme. Dr Guvuriro is also a member of the Future Professoriate Group participating in the Transformation of the Professoriate Programme.  

About the project 

Dr Guvuriro’s main project during his five-month stay at the University of Michigan was on hazardous drinking and economic preferences among urban youth in South Africa. The project recognises that lifestyle behaviours in early life are important drivers of chronic disease later in life, and that harmful use of alcohol is among the main risk factors for non-communicable diseases in the world. According to Dr Guvuriro, persuasive behaviour-change approaches could be useful, especially in the context of developing countries, where the World Health Organisation’s non-communicable diseases ‘Best Buys’ interventions on alcohol use could be ineffective. Behavioural economics and experimental economics techniques could also be beneficial. "With the assistance of my host, Prof Erin Krupka from the University of Michigan School of Information, academics and other staff members, I have made very strong progress in analysing my survey and experimental data on the subject, which I obtained here in South Africa,” said Dr Guvuriro.

Unpacking UMAPS 

UMAPS offers African scholars drawn from across Africa the opportunity to spend five months at the University of Michigan, working and interacting with faculty members who are leaders in their fields. Each year, applications for the fellowship open on 15 August and close on 15 October. The programme started in 2009, hosting a single cohort each year. From 2020, the programme hosted two cohorts of about 15 African scholars each. These scholars are selected annually from an application pool of about 600. 

"It was an amazing experience, one that I wish all of my colleagues in the faculty and the institution at large could have," Dr Guvuriro said. “Other than meeting the faculty staff at the University of Michigan – who are amazing – I got to meet and interact with world leaders in the economics subdiscipline of my interest.” 

He concluded by stating that this is a rare opportunity for scholars, and although competitive, he believes it is worth applying for. “Although I was the first from the UFS to attend, I know that the August to December 2022 cohort has another UFS staff member, which is great. My wish would be for our university to be represented annually.”

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept